Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $10.6050, but opened at $11.22. Bavarian Nordic shares last traded at $11.21, with a volume of 6,054 shares changing hands.
Bavarian Nordic Stock Performance
The business’s fifty day moving average is $10.01 and its 200-day moving average is $9.80. The firm has a market cap of $2.69 billion, a P/E ratio of 11.42 and a beta of 1.20.
Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) last posted its earnings results on Friday, August 21st. The company reported $0.46 earnings per share for the quarter. Bavarian Nordic had a net margin of 24.36% and a return on equity of 11.97%. The firm had revenue of $316.47 million for the quarter.
About Bavarian Nordic
Bavarian Nordic A/S (OTCMKTS:BVNRY) is a Danish biotechnology company that develops, manufactures and commercializes vaccines for infectious diseases. The company serves government agencies, military organizations, healthcare providers and travelers, with products distributed across Europe, North America and other international markets.
Its best-known product is JYNNEOS, also marketed as IMVAMUNE or IMVANEX in certain regions, a non-replicating smallpox and mpox vaccine. Bavarian Nordic also offers vaccines for rabies and tick-borne encephalitis, including RabAvert and Rabipur for rabies prevention and Encepur for protection against tick-borne encephalitis.
Further Reading
- Five stocks we like better than Bavarian Nordic
- Full Throttle: Kratos and GE Fire Up a Next-Gen Defense Engine
- Sandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?
- These 4 Companies Are Monetizing AI Today
- Quantum and Rare Earths? Implications of the Pasqal/USAR Partnership
Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with MarketBeat.com's FREE daily email newsletter.
